Co-delivering a PSMA targeted ADC with lutetium-177-PSMA-617 could radiosensitize metastatic cancer cells systemically at all sites of disease and not be limited by focal external beam radiotherapy delivery. This evidence concerns the gene FOLH1 and metastatic malignant neoplasm.